Scienture Holdings, Inc.·4

Mar 12, 9:32 PM ET

Narasimhan Mani 4

Research Summary

AI-generated summary

Updated

Scienture (SCNX) Co‑CEO Narasimhan Mani Receives Stock Awards

What Happened

  • Narasimhan Mani, President & Co‑CEO and a director of Scienture Holdings, converted 1,357,538 shares of Series X preferred stock into common stock on September 19, 2024 (automatic one‑for‑one conversion related to the company’s merger). That conversion involved derivative securities and is reported with no cash paid.
  • Mr. Mani also had a 20,000‑share disposition reported on March 10, 2025 at $0.00 (transfer of shares to a designee of a lender per the filing's footnote).
  • He received three restricted‑stock awards (all $0.00 price): 750,000 shares (granted April 14, 2025), 300,000 shares (granted October 1, 2025), and 500,000 shares (granted February 20, 2026) — a total of 1,550,000 restricted shares. Vesting: the 750k vests in two equal annual installments beginning April 14, 2026; the 300k vests in two equal annual installments beginning October 1, 2026; the 500k award is a discretionary bonus to be issued in three tranches (June, Sept, Dec 2026) and each tranche vests three years after issuance.

Key Details

  • Transaction dates and types:
    • 2024-09-19: Conversion of Series X Preferred into common — 1,357,538 shares (automatic conversion; derivative conversion entry).
    • 2025-03-10: Disposal/transfer of 20,000 shares @ $0.00.
    • 2025-04-14: Award of 750,000 restricted shares @ $0.00.
    • 2025-10-01: Award of 300,000 restricted shares @ $0.00.
    • 2026-02-20: Award of 500,000 restricted shares (discretionary bonus) @ $0.00.
  • Shares owned after these transactions are not specified in the supplied excerpt of the filing.
  • Notable footnotes:
    • F1: Automatic one‑for‑one conversion of Series X Preferred following merger-related mailing.
    • F2: Some securities are held by Srivatsav, LLC; Mr. Mani may be deemed an indirect owner as its managing member.
    • F3: The 20,000‑share transfer was to a designee of NVK Finance, LLC as consideration for lender consent.
    • F4–F6: Detailed vesting schedules for each restricted share award.
  • Timeliness: The Form 4 was filed on March 12, 2026 covering transactions as early as September 19, 2024 — the filing is marked late, reducing near‑term transparency.

Context

  • The 9/19/24 transaction was a conversion of a preferred stock series into common stock (not an open‑market purchase or sale) and is typically a mechanical outcome of merger terms rather than an opportunistic trade.
  • The $0.00 entries for the 750k, 300k, and 500k items indicate grants of restricted common stock (awards) that vest over time; these are compensatory, not immediate cash purchases, and generally subject to forfeiture until vesting.
  • Transfers to a lender’s designee (the 20k shares) are often related to financing or loan agreements and do not necessarily reflect a market sentiment by the insider.
  • Because these are grants and conversion/transfer events (not open‑market purchases), they are informative about compensation and capital structure but less directly indicative of short‑term insider bullishness or bearishness.